IMMNOV Share Price Performance

SEK 0.19

-0.30 (-60.82%)

SEK 0.42

Fair Value

SEK 0.19

-0.30 (-60.82%)

54.5% undervalued

SEK 0.42

Fair Value

SEK 0.19

SEK 0.42

Fri, 26 Jun 26

Fair ValueSEK 0.42

Share Pricen/a

IMMNOV Community Narratives

AnalystConsensusTarget's

Fair Value

Fair Value SEK 0.42 54.5% undervalued

Blood Cancer Screening Adoption Will Drive Long-Term Upside Potential

About IMMNOV

Founded: 2007
Employees: 17
CEO: Jeff Borcherding
WebsiteView website: www.immunovia.com

Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Recent IMMNOV News & Updates

Announcement • Jun 12

Immunovia Publishes Final Affirm Study Results in Journal of Clinical Oncology Confirming Strong Diagnostic Performance of Pancreasure

Immunovia AB announced that the final results from the AFFIRM clinical study have been published in the Journal of Clinical Oncology: Oncology Advances. The results show 88% sensitivity and 98% specificity for PancreaSure in late-stage pancreatic cancer patients and healthy, average-risk individuals, respectively, consistent with previously reported interim data. The AFFIRM study demonstrated that PancreaSure achieved 88% sensitivity in detecting Stage III and Stage IV pancreatic cancers and 98% specificity in correctly classifying control samples as non-cancerous. The study included blood samples from 619 individuals: 105 Stage III and 119 Stage IV pancreatic cancer samples from the Immunovia biobank, originally acquired from five European pancreatic cancer programs, along with 395 healthy control samples. These results expand and reinforce the previously reported CLARITI and VERIFI data by adding evidence of strong performance in advanced-stage disease. Importantly, the inclusion of a healthy control population for the specificity analysis aligns with methodology commonly used in the broader cancer detection field, enabling more direct benchmarking of PancreaSure against other tests. The AFFIRM study was designed to complement Immunovia's prior clinical validation studies, CLARITI and VERIFI, which focused on Stage I and Stage II pancreatic cancer and evaluated specificity in high-risk individuals – including those with family history, genetic mutations, or pancreatic cysts. AFFIRM addressed two additional objectives: measuring PancreaSure's sensitivity in detecting advanced-stage (Stage III and Stage IV) pancreatic cancer, and assessing specificity in healthy, average-risk individuals. Together, the three studies provide a comprehensive clinical evidence base spanning all major disease stages and both high-risk and average-risk populations.

Recent updates

No updates

Immunovia AB (publ) Stock Price

IMMNOV Share Price Performance

IMMNOV Community Narratives

Blood Cancer Screening Adoption Will Drive Long-Term Upside Potential

Blood Cancer Screening Adoption Will Drive Long-Term Upside Potential

Trending Discussion

Recently Updated Narratives

IMMNOV: Medicare Coverage Prospects For Pancreatic Cancer Test Will Drive Future Upside

Snowflake Analysis

Immunovia AB (publ) Key Details

About IMMNOV

Recent IMMNOV News & Updates

IMMNOV: Medicare Coverage Prospects For Pancreatic Cancer Test Will Drive Future Upside

Immunovia Announces New Performance Data for PancreaSure Ahead of Upcoming Application for Medicare Coverage

Immunovia Publishes Final Affirm Study Results in Journal of Clinical Oncology Confirming Strong Diagnostic Performance of Pancreasure

Recent updates

Immunovia AB (publ) Competitors

CellaVision

Humana

Stille

Surgical Science Sweden